Sagility Limited Declares Interim Dividend of ₹0.15/Share; Acquires Chirok Health LLC
Sagility Limited reported its Q2 FY27 results with a profit of ₹2,842.12 million. The company declared an interim dividend of ₹0.15 per share. Sagility also announced an agreement to acquire Chirok Health LLC for US$32.35 million and previously acquired CareSeed LLC for US$30.0 million.
The announcement includes financial results, dividend declaration, and two significant acquisitions, all of which are material events for the company.
The company announced positive financial results, a dividend payout, and strategic acquisitions, all of which are positive indicators for investors.
Sagility Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors, in their meeting held on October 22, 2026, approved these results.
The company also declared an interim dividend of ₹0.15 per equity share, with a record date set for October 30, 2026, and payment expected on or before November 21, 2026. This dividend payment is estimated to result in a cash outflow of approximately ₹702.20 million.
In a significant strategic move, Sagility Limited, through its wholly owned subsidiary Sagility (US) Holdings Inc., entered into a definitive agreement to acquire 100% of the equity shares of Chirok Health LLC for a total consideration of US$32.35 million (₹3,102.44 million). This includes a contingent consideration of up to US$12.35 million (₹1,184.39 million) tied to performance targets. Chirok Health LLC specializes in Clinical Documentation Integrity (CDI), medical coding, Revenue Cycle Management (RCM), and audit and quality assurance services, primarily serving the provider category in the US. The transaction is subject to closing conditions and has not yet been consummated.
Previously, on June 11, 2026, Sagility LLC acquired 100% of CareSeed LLC, a US-based healthcare technology company, for US$30.0 million (₹2,873.38 million). CareSeed provides quality measurement (HEDIS) reporting and risk adjustment solutions for health plans.
The financial results for the quarter ended September 30, 2026, showed a profit for the period of ₹2,842.12 million for the consolidated entity. Revenue from operations for the quarter was ₹20,320.97 million.
What to do with a filing like this
SAGILITY LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SAGILITY LIMITED. Read the original for the full detail.